Showing posts with label glaxosmithkline. Show all posts
Showing posts with label glaxosmithkline. Show all posts
Sunday, August 22, 2010
NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline
"Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma. The research grant to NCCN will evaluate the effectiveness of pazopanib in solid tumors including renal, sarcoma, thyroid, neuroendocrine, and ovarian cancers."
Subscribe to:
Posts
(
Atom
)
